Breadcrumb

RESP  |  Translational Research in Respiratory Diseases Program

RESP Program News

We are proud to celebrate the scientific achievements of our researchers and trainees in publications, grant competitions, honors and awards, and appointments, as well as in the mainstream press.

Old drug, new therapy: RI-MUHC-sponsored phase III clinical trial ready to test repurposed dapsone to tone down lung inflammation caused by COVID-19

Reformulated and patented version of well-known generic drug could prove to be a quick, safe and cost-effective way to accelerate recovery and prevent hospitalizations

Research suggests greater access to specific HIV and tuberculosis medications is needed worldwide

Postdoctoral fellows at the RI-MUHC carried out primary statistical analyses for study published in The Lancet

Canada Research Chairs Program announces new and renewed chairs

Congratulations to five RI-MUHC researchers in the spring 2020 round!

Recipient of the 2020-2021 Dr. Margaret Becklake Fellowship: Mikashmi Kohli

A postdoctoral fellow from the RI-MUHC is recognized for international work on TB diagnostics

Three COVID-19 projects at the RI-MUHC to receive CIHR funding

A $109M fund aims to mitigate impact of the pandemic on care delivery in Canada and beyond, as well as contribute to better understanding of the disease

Rifampin for Latent TB: Shorter and safer than the standard treatment, but also cheaper

A new study shows that rifampin regimen is cheaper than isoniazid for latent tuberculosis

Why do some non-smokers get COPD while many heavy smokers don’t?

A new study highlights a strong risk factor for COPD related to lung development

Results of MI4 Emergency COVID-19 Research Funding (Round 2)

RI-MUHC researchers awarded MUHC Foundation funding for a second round of projects with potential impact in a short timeframe

We Care About Rare!

Researchers, advocates and patients gather on Rare Disease Research Day at the RI-MUHC

Explore news and events at the RI-MUHC